Clozapine → Mental impairment — Audit-grade candidate (scan)

← All findings ⬇ Download signed audit packet

Ledger entry · candidate

Clozapine → Mental impairment — Audit-grade candidate (scan)

Drug: clozapine · AE: Mental impairment

Discovered via single-drug scan of clozapine. PRR = 18.91 (95% CI 17.42–20.53), n = 569 cases. Pre-reg locked at submission time.

Disproportionality

PRR: 18.912443546588833 (95% CI 17.42–20.53)
Yates χ²: 9414.981968365477
Cases (case-drug + AE): n = 569
Verdict: PASSES_ALL_GATES — PRR=18.91 (95% CI 17.42–20.53), n=569 cases; flagged for clinical expert review, NOT for external escalation without manual verification

Top reactions in cohort

MedDRA PT	n
No reactions surfaced in cohort.

Source: openFDA FAERS, Caliper Engine v0. Pre-registration sha1 locked at submission time; ledger entry signed with platform Ed25519 key.

Independent Verification & Validation

Every finding includes an in-engine adversary review at no cost. For findings you plan to cite in a regulatory submission, scientific publication, or board-grade decision, we offer an additional layer of independent, audit-grade verification — reviewed by an externally-trained system that has never seen your data, your training corpus, or our hardware, and cryptographically signed.

Reference: ab0b23ceb2563aa50477e3fda3dd41b48d7b7850